Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.
Nakaya A, Shibayama H, Uoshima N, Yamamura R, Yoshioka S, Imada K, Shimura Y, Hotta M, Matsui T, Kosugi S, Hanamoto H, Uchiyama H, Yoshihara S, Fuchida SI, Onda Y, Tanaka Y, Ohta K, Matsuda M, Kanda J, Yoko A, Kiyota M, Kawata E, Takahashi R, Fukushima K, Tanaka H, Yagi H, Takakuwa T, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M. Nakaya A, et al. Among authors: onda y. Leuk Res Rep. 2023 Nov 17;20:100395. doi: 10.1016/j.lrr.2023.100395. eCollection 2023. Leuk Res Rep. 2023. PMID: 38076634 Free PMC article.
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry.
Nakaya A, Kohara T, Shibayama H, Onda Y, Kanda J, Kaneko H, Imada K, Kida T, Kosugi S, Ishikawa J, Yamamura R, Shimazu Y, Tanaka H, Fuchida SI, Shimura Y, Kiyota M, Wada K, Ito T, Uoshima N, Yagi H, Yoshihara S, Ohta K, Shimazaki C, Hino M, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S; Kansai Myeloma Forum Investigators. Nakaya A, et al. Among authors: onda y. Int J Hematol. 2020 Oct;112(4):435-438. doi: 10.1007/s12185-020-02996-6. Epub 2020 Sep 21. Int J Hematol. 2020. PMID: 32959221
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Takakuwa T, et al. Among authors: onda y. Eur J Haematol. 2021 Apr;106(4):555-562. doi: 10.1111/ejh.13586. Epub 2021 Jan 31. Eur J Haematol. 2021. PMID: 33476404
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.
Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida SI, Nakaya A, Itou T, Yamamura R, Tanaka H, Shibayama H, Shimazu Y, Uchiyama H, Yoshihara S, Adachi Y, Matsuda M, Hanamoto H, Uoshima N, Kosugi S, Ohta K, Yagi H, Kanakura Y, Matsumura I, Hino M, Nomura S, Shimazaki C, Takaori-Kondo A, Kuroda J; Kansai Myeloma Forum. Onda Y, et al. Ther Adv Hematol. 2022 Jun 24;13:20406207221104584. doi: 10.1177/20406207221104584. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35785245 Free PMC article.
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide.
Shimazu Y, Kanda J, Kaneko H, Imada K, Yamamura R, Kosugi S, Shimura Y, Ito T, Fuchida SI, Uchiyama H, Fukushima K, Yoshihara S, Hanamoto H, Tanaka H, Uoshima N, Ohta K, Yagi H, Shibayama H, Onda Y, Tanaka Y, Adachi Y, Matsuda M, Iida M, Miyoshi T, Matsui T, Takahashi R, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J; Kansai Myeloma Forum. Shimazu Y, et al. Among authors: onda y. Ther Adv Hematol. 2022 Dec 13;13:20406207221142487. doi: 10.1177/20406207221142487. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36530751 Free PMC article.
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.
Shimazu Y, Kanda J, Kosugi S, Ito T, Kaneko H, Imada K, Shimura Y, Fuchida SI, Fukushima K, Tanaka H, Yoshihara S, Ohta K, Uoshima N, Yagi H, Shibayama H, Yamamura R, Tanaka Y, Uchiyama H, Onda Y, Adachi Y, Hanamoto H, Takahashi R, Matsuda M, Miyoshi T, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J. Shimazu Y, et al. Among authors: onda y. Sci Rep. 2023 Mar 29;13(1):5159. doi: 10.1038/s41598-023-32426-6. Sci Rep. 2023. PMID: 36991096 Free PMC article.
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, Kosugi S, Yamamura R, Matsuda M, Hanamoto H, Adachi Y, Anzai N, Hotta M, Fukushima K, Yagi H, Yoshihara S, Tanaka Y, Takakuwa T, Tanaka H, Shibayama H, Uoshima N, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. Shimazu Y, et al. Among authors: onda y. Cancer Immunol Immunother. 2024 May 17;73(7):135. doi: 10.1007/s00262-024-03711-8. Cancer Immunol Immunother. 2024. PMID: 38758239 Free PMC article.
Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors.
Morishima S, Fukuda T, Doki N, Mori T, Onizuka M, Kawakita T, Kato C, Ozawa Y, Tanaka M, Kurokawa M, Kamimura T, Inoue M, Tanaka J, Ichinohe T, Atsuta Y, Morishima Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Morishima S, et al. Bone Marrow Transplant. 2021 Mar;56(3):646-654. doi: 10.1038/s41409-020-01070-3. Epub 2020 Oct 9. Bone Marrow Transplant. 2021. PMID: 33037403
204 results